This is the authors' abstract. We don't add key points for this paper.
Rifampin molecular-phenotypic discordance was rare, and most isolates had INH resistance. Patients who did not receive an expanded regimen had poor outcomes. These mutations may have clinical importance, and expanded treatment regimens should be considered.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Shah et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: